• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突破性癌症疼痛对一般活动和疼痛管理的影响:有和无突破性癌症疼痛患者的比较。

Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain.

机构信息

1 Department of Palliative Medicine, National Cancer Center Hospital East , Kashiwa, Japan .

2 Department of Palliative Medicine, Tohoku University School of Medicine , Sendai, Japan .

出版信息

J Palliat Med. 2018 Nov;21(11):1636-1640. doi: 10.1089/jpm.2017.0675. Epub 2018 Jul 5.

DOI:10.1089/jpm.2017.0675
PMID:29975582
Abstract

BACKGROUND

Breakthrough cancer pain (BTcP) is a predictor of interference with general activities and poor pain management. The extent of this influence has not yet been determined.

OBJECTIVE

This study aimed to investigate the influence of BTcP on general activities, and pain management in patients with controlled background pain.

DESIGN

Single-center prospective observational study.

SETTING/SUBJECTS: The study cohort comprised 258 consecutive patients (female, 40.0%; mean age, 64.5 years) who had received opioid medication for cancer pain for over 2 weeks.

MEASUREMENTS

A recommended diagnostic algorithm was used to quantitate and compare interference with general activities, average background pain intensity over the previous 24 hours (24h-PI), and achievement of personalized pain goals (PPGs) (24h-PI≤PPG) of 119 patients with and 139 patients without BTcP.

RESULTS

Interference with general activities, 24h-PI, and PPG scores [mean (standard deviation)] in patients with BTcP were 2.8 (2.2), 3.0 (1.7), and 1.8 (1.4), respectively, which are all significantly higher than for those without BTcP [1.3 (2.0), p < 0.01; 1.7 (1.6), p < 0.01; 1.5 (1.3), p = 0.03], respectively. A significantly smaller percentage of patients with BTcP than without BTcP achieved their PPGs (36.1% vs. 67.6%, p < 0.01).

CONCLUSIONS

BTcP has a negative impact on general activities and pain management. Healthcare providers should recognize that management of BTcP is important in improving general activities and management of cancer pain.

摘要

背景

突破性癌痛(BTcP)是干扰日常活动和疼痛管理不佳的预测指标。但其影响程度尚未确定。

目的

本研究旨在调查 BTcP 对背景疼痛得到控制的患者日常活动和疼痛管理的影响。

设计

单中心前瞻性观察研究。

设置/研究对象:研究队列包括 258 例连续接受阿片类药物治疗癌症疼痛超过 2 周的患者(女性占 40.0%;平均年龄 64.5 岁)。

测量

采用推荐的诊断算法来量化和比较 119 例有 BTcP 和 139 例无 BTcP 患者的日常活动干扰、过去 24 小时平均背景疼痛强度(24h-PI)和个性化疼痛目标(PPG)的达成情况(24h-PI≤PPG)。

结果

BTcP 患者的日常活动干扰、24h-PI 和 PPG 评分[平均值(标准差)]分别为 2.8(2.2)、3.0(1.7)和 1.8(1.4),均显著高于无 BTcP 患者[1.3(2.0),p<0.01;1.7(1.6),p<0.01;1.5(1.3),p=0.03]。有 BTcP 的患者达到 PPG 的比例显著低于无 BTcP 的患者(36.1% vs. 67.6%,p<0.01)。

结论

BTcP 对日常活动和疼痛管理有负面影响。医疗保健提供者应认识到,管理 BTcP 对于改善日常活动和癌症疼痛管理非常重要。

相似文献

1
Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain.突破性癌症疼痛对一般活动和疼痛管理的影响:有和无突破性癌症疼痛患者的比较。
J Palliat Med. 2018 Nov;21(11):1636-1640. doi: 10.1089/jpm.2017.0675. Epub 2018 Jul 5.
2
Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.突破性癌痛个体化治疗:哪些因素影响药物选择?一项终末期癌症患者的观察性、前瞻性和横断面研究。
Postgrad Med J. 2018 Oct;94(1116):566-570. doi: 10.1136/postgradmedj-2018-135659. Epub 2018 Oct 13.
3
Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.爆发性疼痛对社区癌症患者的影响:来自全国爆发性疼痛研究的结果。
Postgrad Med. 2017 Jan;129(1):32-39. doi: 10.1080/00325481.2017.1261606. Epub 2016 Dec 5.
4
Breakthrough Cancer Pain: Ten Commandments.突破性癌痛:十诫
Value Health. 2016 Jul-Aug;19(5):531-6. doi: 10.1016/j.jval.2016.03.002. Epub 2016 May 25.
5
Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.影响阿片类药物治疗爆发性癌痛的因素:IOPS-MS 研究的二次分析。
Eur J Pain. 2019 Apr;23(4):719-726. doi: 10.1002/ejp.1339. Epub 2018 Dec 28.
6
Breakthrough cancer pain: review and calls to action to improve its management.突破性癌痛:改善其管理的综述和行动呼吁。
Clin Transl Oncol. 2020 Aug;22(8):1216-1226. doi: 10.1007/s12094-019-02268-8. Epub 2020 Jan 30.
7
Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.头颈部癌症患者的突破性疼痛。IOPS MS 研究的二次分析。
Oral Oncol. 2019 Aug;95:87-90. doi: 10.1016/j.oraloncology.2019.06.006. Epub 2019 Jun 11.
8
Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.姑息治疗中爆发痛(BTcP)的特征与治疗
Med Arch. 2017 Aug;71(4):246-250. doi: 10.5455/medarh.2017.71.246-250.
9
Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.临床实践中用于缓解突破性癌症疼痛的芬太尼颊片剂:非干预性前瞻性研究 ErkentNIS 的结果。
Support Care Cancer. 2018 Feb;26(2):491-497. doi: 10.1007/s00520-017-3853-y. Epub 2017 Aug 28.
10
Current management of breakthrough cancer pain according to physicians from pain units in Spain.西班牙疼痛科医师对爆发性癌痛的管理现状。
Clin Transl Oncol. 2019 Sep;21(9):1168-1176. doi: 10.1007/s12094-019-02044-8. Epub 2019 Feb 19.

引用本文的文献

1
Validation of the Spanish Version of the Breakthrough Pain Assessment Tool in Patients With Cancer.癌症患者中突破性疼痛评估工具西班牙语版本的验证
Cureus. 2024 Sep 10;16(9):e69135. doi: 10.7759/cureus.69135. eCollection 2024 Sep.
2
Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial.芬太尼吸入剂治疗爆发性癌痛的疗效和安全性:一项多中心、随机、双盲、安慰剂对照试验。
BMC Palliat Care. 2024 Sep 7;23(1):222. doi: 10.1186/s12904-024-01554-9.
3
Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital.
在一家三级癌症医院的住院环境中,计划使用阿片类药物和突破性阿片类药物治疗癌症疼痛。
Curr Oncol. 2024 Mar 5;31(3):1335-1347. doi: 10.3390/curroncol31030101.
4
Fentanyl in cancer pain management: avoiding hasty judgments and discerning its potential benefits.芬太尼在癌症疼痛管理中的应用:避免仓促判断并识别其潜在益处。
Drugs Context. 2023 Dec 14;12. doi: 10.7573/dic.2023-10-2. eCollection 2023.
5
Once again... breakthrough cancer pain: an updated overview.再一次……突破性癌痛:最新概述。
J Anesth Analg Crit Care. 2023 Jul 21;3(1):23. doi: 10.1186/s44158-023-00101-x.
6
Clinical relevance of deep learning models in predicting the onset timing of cancer pain exacerbation.深度学习模型在预测癌症疼痛加剧发作时间中的临床相关性。
Sci Rep. 2023 Jul 17;13(1):11501. doi: 10.1038/s41598-023-37742-5.
7
Cancer pain: Results of a prospective study on prognostic indicators of pain intensity including pain syndromes assessment.癌症疼痛:一项关于疼痛强度预后指标的前瞻性研究结果,包括疼痛综合征评估。
Palliat Med. 2022 Oct;36(9):1396-1407. doi: 10.1177/02692163221122354. Epub 2022 Sep 14.
8
Deploying the Behavioral and Environmental Sensing and Intervention for Cancer Smart Health System to Support Patients and Family Caregivers in Managing Pain: Feasibility and Acceptability Study.部署癌症智能健康系统的行为与环境传感及干预以支持患者和家庭护理人员管理疼痛:可行性与可接受性研究
JMIR Cancer. 2022 Aug 9;8(3):e36879. doi: 10.2196/36879.
9
Efficacy of adenosylmethionine combined with Si Mo Tang in treatment of neonatal jaundice.腺苷蛋氨酸联合四磨汤治疗新生儿黄疸的疗效
Am J Transl Res. 2022 Jun 15;14(6):3926-3935. eCollection 2022.
10
Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study.患者对突破性癌痛治疗的满意度:IOPS-MS研究的二次分析
Cancer Manag Res. 2022 Mar 24;14:1237-1245. doi: 10.2147/CMAR.S353036. eCollection 2022.